REG - MD Medical Group - CORRECTION TO MDMG ANNOUNCEMENT

MD Medical InvestmentsAnnouncement

10/11/2020 17:15

RNS Number : 8941E
  
MD Medical Group Investments PLC
  
10 November 2020
  
 

 


 
 
 
CORRECTION TO MDMG ANNOUNCEMENT
10 November 2020, Moscow - MD Medical Group Investments Plc ("MD Medical Group", "MDMG" or the "Company" - MDMG), a leading Russian private healthcare provider, announces a correction on the price per GDR in the "MDMG Announcement" released on November 10 2020 at 13-00 UK time, containing the notification with the Financial Conduct Authority of the acquisition of MDMG Global Depositary Receipts ('GDRs') by Vitaly Ustimenko, member of the Board of Directors. With the correction the announcement reads as follows:




Transaction date


Number of GDRs


Price per GDR




09 November 2020


1 000


USD 6.055




 
Following this transaction, Vitaly Ustimenko holds 3 607 GDRs, or 0.005% of the Company's issued and outstanding share capital.
This announcement is made in accordance with the requirements of article 19(6) of the Market Abuse Regulation.
 
This announcement contains inside information.
 
For further information please contact:




Investors


Media




            
Dmitry Yakushkin 
MD Medical Group Investments Plc
+7 (495) 139-87-40,  ext. 16329 

d.yakushkin@mcclinics.ru


EM



Tom Blackwell: +7 919 102 9064
Sergii Pershyn: +1 929 855 8188
MDMG@em-comms.com




 
 
 
 
 
About MD Medical Group
 
MD Medical Group is a leading provider in the highly attractive Russian private healthcare service market. The company manages 42 modern healthcare facilities, including 6 hospitals and 36 out-patient clinics in Moscow and the Moscow Region, St. Petersburg, Ufa, Perm, Samara and the Samara Region, Irkutsk, Novosibirsk, Irkutsk, Yaroslavl, Ryazan, Kostroma, Novokuznetsk, Krasnoyarsk, Omsk, Barnaul, Vladimir, Tyumen, Voronezh, Nizhny Novgorod, Volgograd, Tula, Kazan, Vladivostok, Krasnodar and Rostov-on-Don.
The Company's shares have been listed on the London Stock Exchange (LSE ticker "MDMG") in the form of Global Depositary Receipts (GDRs) since 12 October 2012.
 
Forward-Looking Statements:
 
This press release contains forward looking statements, which are based on the Company's current expectations and assumptions and may involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. The forward looking statements contained in this press release are based on past trends or activities and should not be taken that such trends or activities will continue in the future. It is believed that the expectations reflected in these statements are reasonable, but they may be affected by a number of variables which could cause actual results or trends to differ materially, including, but not limited to: conditions in the market, market position of the Company, earnings, financial position, cash flows, return on capital and operating margins, anticipated investments and economic conditions; the Company's ability to obtain capital/additional finance; a reduction in demand by customers; an increase in competition; an unexpected decline in revenue or profitability; legislative, fiscal and regulatory developments, including, but not limited to, changes in environmental and health and safety regulations; exchange rate fluctuations; retention of senior management; the maintenance of labour relations; fluctuations in the cost of input costs; and operating and financial restrictions as a result of financing arrangements.
No statement in this press release is intended to constitute a profit forecast, nor should any statements be interpreted to mean that earnings or earnings per share will necessarily be greater or lesser than those for the relevant preceding financial periods for the Company. Each forward looking statement relates only as of the date of the particular statement.
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
MSCKZMMMVGNGGZM